Rabia Nazik Yüksel

Rabia Nazik Yüksel

Auto-generated profile, based on publicly available information

Rabia Nazik Yüksel

Department of Psychiatry, University of Health Science, Ankara City Hospital, Ankara, Turkey.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Psychiatry Research
Verified
Journal Article
Closed access
GEGamze Erzin
Gamze Erzin
VKVahap Ozan Kotan
Vahap Ozan Kotan
CTCanan Topçuoğlu
Canan Topçuoğlu
GOGuven Ozkaya
Guven Ozkaya
ÖEÖzcan EREL
Özcan EREL
EGErol Göka
Erol Göka

8 March 2018 in Nordic Journal of Psychiatry
Verified
Journal Article
Closed access
KÜKübranur Ünal
Kübranur Ünal
GEGamze Erzin
Gamze Erzin
RYRabia Nazik Yüksel
Rabia Nazik Yüksel
MAMurat Alisik
Murat Alisik
ÖEÖzcan Erel
Özcan Erel
Introduction: This study aims to investigate the dynamic thiol/disulphincide homeostasis in patients with schizophrenia who have positive psychotic indications. Materials and methods: Forty-four patients (26 males, 18 females; mean age = 34.40 ± 8.98 years) accepted at the Department of Psychiatry of the Ankara Numune Training and Research Hospital and 33 healthy controls (15 males, 18 females; mean age of 30.30 ± 8.48 years) were included in the study. Serum native thiol and total thiol were measured with a novel colorimetric, automated method. The disulfide levels and disulfide/native thiol ratios were also calculated from these measured parameters. Results: Serum native thiol and the total thiol concentration were significantly lower in schizophrenia compared with the control group (p < .05). Disulphide levels and disulfide/native thiol ratios were significantly higher in schizophrenia compared with the control group (p < .05). When the patients were divided into two groups according to those who used medication and those who did not for the last two months, it was found to be significantly higher in those who used disulfide and disulfide/native thiol medication than those who did not use medication. Conclusion: The disulfide/native thiol ratio in patients with schizophrenia who have been using medication for the last 2 months has been found to be significantly higher than controls who have not been using medication, may be indicating that the level of native thiol does not increase in a correlation as high as the increase in disulfide levels. It demonstrates that thiol/disulfide equilibrium has shifted towards the disulfide. The excess disulfide amounts might associated with both disease itself and the using medication.

21 January 2016 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
RYRabia Nazik Yüksel
Rabia Nazik Yüksel
ZKZeynep Elyas Kaya
Zeynep Elyas Kaya
NDNesrin Dilbaz
Nesrin Dilbaz
MYMerve Cingi Yirün
Merve Cingi Yirün
Cabergoline is an orally administered synthetic dopamine agonist that is used for the treatment of hyperprolactinemia, Parkinson’s disease and antipsychotic-induced prolactin elevation. One of the main characteristics of cabergoline is its long duration of effect. It is highly effective in suppressing prolactin levels up to 21 days after a single 1 mg oral dose. The prolonged elimination half-life offers an advantage of once-daily dosing, but it might be a handicap in terms of washout of adverse effects such as psychosis. Cabergoline has been associated with adverse reactions consistent with other dopaminergic agonists including cardiovascular, gastrointestinal and neuropsychiatric effects. It is known that dopaminergic treatment is a remarkable risk factor for psychosis. A number of reports implicate dopamine agonists in the development of psychosis, but there is no knowledge in the literature of dopamine agonist-induced mania. In this case, we report the first manic episode occurring after cabergoline use for hyperprolactinemia treatment. In susceptible individuals, cabergoline can cause manic episodes and cabergoline should be used more carefully considering the risk–benefit ratio.

1 December 2019 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
RYRabia Nazik Yüksel
Rabia Nazik Yüksel
ATAyşe Pınar Titiz
Ayşe Pınar Titiz
EYElif Tatlıdil Yaylacı
Elif Tatlıdil Yaylacı
KÜKübranur Ünal
Kübranur Ünal
TTTuran Turhan
Turan Turhan
EGErol Göka
Erol Göka

31 August 2020 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
GEGamze Erzin
Gamze Erzin
GOGuven Ozkaya
Guven Ozkaya
CTCanan Topçuoğlu
Canan Topçuoğlu
RYRabia Nazik Yüksel
Rabia Nazik Yüksel
ÖEÖzcan EREL
Özcan EREL
SGSinan Gülöksüz
Sinan Gülöksüz
Gamze Erzin, Güven Özkaya, Canan Topçuoğlu, Rabia Nazik Yüksel, Özcan Erel, Emine Feyza Yurt, Erol Göka, Sinan Gülöksüz. Clin Psychopharmacol Neurosci 2020;18:395-401. https://doi.org/10.9758/cpn.2020.18.3.395

10 March 2020 in Psychiatric Quarterly
Verified
Journal Article
Closed access
PDF file
RYRabia Nazik Yüksel
Rabia Nazik Yüksel
DGDiğdem Göverti
Diğdem Göverti
AKAybeniz Civan Kahve
Aybeniz Civan Kahve
IÇIşık Batuhan Çakmak
Işık Batuhan Çakmak
ÇYçiğdem yücel
çiğdem yücel
EGErol Göka
Erol Göka